Switching to Hemlibra Can Add Significant Costs for Patients in US
Switching to Hemlibra (emicizumab) can add more than $100,000 a year to healthcare costs for people with hemophilia…
Articles by Marisa Wexler, MS
Study: Eloctate, Alprolix Effective at Preventing Surgical Bleeds
The extended half-life replacement therapies Eloctate and Alprolix can be used to effectively manage bleeding during surgery in people with…
FLT180a, Gene Therapy for Hem B, Sustaining Higher FIX Levels
A single dose of Freeline Therapeutics’ experimental gene therapy FLT180a increased the levels of factor IX (FIX) — the…
Switch to Fitusiran Reduced Bleed Rates in Hem A and B
Most people with hemophilia A or B who switched from an approved prophylactic (preventive) therapy regimen to once-monthly…
Factor IX Levels Normal After Gene Therapy for First 3 Patients in Trial
The first three participants in the B-LIEVE trial all have factor IX (FIX) levels within the normal range more than…
Concizumab Reduces Bleeding in Hem A and B Patients: Phase 3 Trial
Once-daily preventive treatment with Novo Nordisk’s experimental therapy concizumab significantly reduced bleeding rates in people with both hemophilia A…
Hemlibra for Mild, Moderate Hem A Supported by HAVEN 6 Study Data
Most people with moderate or mild hemophilia A who received preventive treatment with Hemlibra (emicizumab) in the HAVEN 6…
Hemlibra Can Now Treat People in Japan With Acquired Hemophilia A
Japan’s Ministry of Health, Labor and Welfare has extended Hemlibra (emicizumab)’s approval to include routine prophylaxis to prevent or lower…
2nd Hem B Patient Group Begins Dosing in Gene Therapy Trial
Dosing has begun in a second group of hemophilia B patients enrolled in a Phase 1/2 dose-confirmation trial of…
Efanesoctocog Alfa Earns Breakthrough Therapy Status
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to efanesoctocog alfa, an experimental replacement therapy…